Tailoring survivorship care for older long-term survivors of breast and colorectal cancer [0.03%]
针对老年乳腺癌和结直肠癌长期生存者的康复治疗优化措施研究
Samuel X Stevens,Ashanya Malalasekera,Sim Yee Tan et al.
Samuel X Stevens et al.
Association between palliative care consultation and care transition outcomes among hospitalized advanced cancer patients [0.03%]
住院晚期癌症患者的姑息治疗咨询与护理转归之间的关系
Hak Jun Kim,Jin-Ah Sim,Sun Young Lee et al.
Hak Jun Kim et al.
Background: The period after hospital discharge is a high-risk phase for patients with advanced cancer, often involving acute-care use that reflects transitional care quality. The impact of inpatient palliative care (PC) ...
Sequential chemo-durvalumab, reduced dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial) [0.03%]
用于不适合接受PACIFIC方案的无法手术的III期NSCLC患者的序贯化疗度伐利尤单抗、减量放疗和巩固治疗度伐利尤单抗（DEDALUS研究）
Francesco Agustoni,Jessica Saddi,Diego Luigi Cortinovis et al.
Francesco Agustoni et al.
Introduction: The PACIFIC study established the standard of care for unresectable, stage III non-small cell lung cancer. The DEDALUS trial is a Phase 2, open-label, multicenter study enrolling patients who are eligible fo...
Psychosocial factors and overall mortality after prostate cancer diagnosis among predominantly low-income Black and White adults [0.03%]
影响低收入黑白人前列腺癌患者预后的心理社会因素分析
Douglas Demoulin,Loren Lipworth,Melinda C Aldrich et al.
Douglas Demoulin et al.
Introduction: Psychosocial factors may influence PCa survival, but evidence is limited for low-income populations. Methods: This study ...
Personalized risk prediction of financial toxicity in patients with cancer: an interpretable machine learning study [0.03%]
基于可解释机器学习的癌症患者财务毒性的个性化预测研究
Haluk Damgacioglu,Kalyani Sonawane,Gerard A Silvestri et al.
Haluk Damgacioglu et al.
Background: Financial toxicity (FT), the economic stress from medical care, is common among people with cancer and is associated with worse health outcomes. While risk factors for FT are known, personalized FT risk predic...
Cancer risk associated with abatacept among older individuals with rheumatoid arthritis in the United States [0.03%]
美国老年人类风湿关节炎患者使用阿巴西普的致癌风险研究
Shyfuddin Ahmed,Xavier Mariette,Raphaele Seror et al.
Shyfuddin Ahmed et al.
Objective: To examine the association between abatacept therapy and cancer risk among individuals with rheumatoid arthritis (RA). Methods: ...
Financial reimbursement for clinical trial participation costs: a pilot feasibility study [0.03%]
临床试验参与成本的经济补偿：一项试点可行性研究
Courtney P Williams,Nicole L Henderson,Nusrat Jahan et al.
Courtney P Williams et al.
Background: Clinical trial participants rarely represent the real-world treatment population, potentially due to costs associated with participation. Monetary reimbursement for trial-related costs could address financial ...
Exploration of BMI and circulating metabolic factors as predictors of metformin benefit in CCTG MA.32 [0.03%]
探索BMI和循环代谢因素作为预测CCTG MA.32研究中二甲双胍疗效的标志物
Pamela J Goodwin,Marguerite Ennis,Bingshu E Chen et al.
Pamela J Goodwin et al.
Background: In the MA.32 randomized adjuvant breast cancer (bc) trial, metformin (vs placebo) did not impact invasive disease free (IDFS) or overall survival (OS) in estrogen/progesterone receptor (ER/PgR) positive or neg...
Hearing/vestibular problems, racial differences, and associations with physical function impairment among breast cancer survivors [0.03%]
乳腺癌幸存者听觉/前庭功能障碍的种族差异及与身体功能损伤的关系
Jincong Q Freeman,Fangyuan Zhao,Wenji Guo et al.
Jincong Q Freeman et al.
Background: Breast cancer survivors face many health challenges, including tinnitus, hearing loss, and vertigo which will grow with an aging population and improved treatment outcomes. However, the prevalence of hearing/v...
Heterogeneity of treatment effect? What baseline prognostic factors tell us about immunotherapy benefit [0.03%]
疗效异质性何来？预测因素如何预示免疫治疗的疗效益处
Chee Khoon Lee,R John Simes
Chee Khoon Lee